At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed...
During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma...
At the AACR Annual Meeting 2026, we conducted "Bite-sized Research" interviews with attendees for morsels of knowledge about their...
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
A recap of the last day of the AACR Annual Meeting 2026, including plenaries on innovative treatment modalities and...
A recap from the fifth day of the AACR Annual Meeting 2026, including a plenary on early-onset cancers, clinical...
A recap of the fourth day of the AACR Annual Meeting 2026, including a plenary on AI, the NCI...
A recap from the third day of the AACR Annual Meeting 2026, including the Opening Plenary, Clinical Trial Plenaries,...